BUSINESS WIRE
HEIDELBERG, Germany--(
BUSINESS WIRE)--Novaliq GmbH today announced the commencement of a Phase 1 study for
CyclASol (Cyclosporin solution) following US and European patent
approval of the solution for the treatment of dry eye syndrome.
While conventional cyclosporin formulations are emulsions, CyclASol is
the first and only 0.05% clear cyclosporin solution. CyclASol is
available in multi-dose and preservative free bottles for the treatment
of dry eye syndrome. CyclASol has demonstrated long-term stability plus
superior wettability, pharmacokinetics, and biocompatibility compared to
conventional emulsions.
CyclASol was developed from Novaliq’s broad range Semi Fluorinated
Alkane (SFA) drug delivery platform EyeSol®, offering significant
competitive advantages for multiple drug candidates within
ophthalmology, primarily by enhancing the therapeutic effect of poorly
soluble drugs.
“We are pleased to receive the USA & European patent and to announce the
start of phase 1 CyclASol study,” said Bernhard Günther, CEO of Novaliq
GmbH. “These are both significant new milestones for Novaliq as we build
our innovative drug delivery portfolio.” In 2013 Novaliq finalized their
fifth round of financing for €13.9 million ($18.1 million) with the
intent to strengthen both their prescription and OTC product development
programs based on SFA technology.
“We congratulate Novaliq on obtaining patent approval for CyclASol and
start of their clinical trials,” commented Mathias Hothum, Managing
Director of Dievini Hopp BioTech Holding GmbH & Co. KG, the investment
company of SAP co-founder Dietmar Hopp. “We are pleased to support
Novaliq as it pioneers new topical ocular drug delivery technology. We
endorse Novaliq’s strategy to establish a portfolio of consumer and
prescription product portfolios within ophthalmology. These products are
intended to cover unmet needs with one major advantage being they will
be preservative free,” Mathias Hothum added furthermore.
About Novaliq GmbH
Novaliq is a drug delivery company whose
goal is to develop innovative pharmaceutical formulations. Its patented
semifluorinated alkanes (SFAs) can be used in various routes of
administration for the transport of drugs or oxygen for therapeutic
purposes. Novaliq currently develops innovative ophthalmic formulations
as well as solutions for organ preservation and has several product
candidates with excellent market potential in various stages of
development. Novaliq welcomes invitations from interested parties to
enter into discussions about significant additional development or
partnership opportunities.
About Dievini Hopp BioTech Holding GmbH & Co. KG
Dievini
is an active investor in Life and Health Sciences companies, with a
focus on innovative therapeutics and diagnostics shown to lead to novel
treatment regimens allowing doctors to treat patients with
life-threatening diseases more safely and efficiently than they are
currently able.